BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 12545158)

  • 21. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
    Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
    Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
    Song Y; Shen K; He CX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
    Barker SD; Coolidge CJ; Kanerva A; Hakkarainen T; Yamamoto M; Liu B; Rivera AA; Bhoola SM; Barnes MN; Alvarez RD; Curiel DT; Hemminki A
    J Gene Med; 2003 Apr; 5(4):300-10. PubMed ID: 12692864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter.
    Berry NB; Cho YM; Harrington MA; Williams SD; Foley J; Nephew KP
    Gynecol Oncol; 2004 Mar; 92(3):896-904. PubMed ID: 14984958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.
    Drabek D; Guy J; Craig R; Grosveld F
    Gene Ther; 1997 Feb; 4(2):93-100. PubMed ID: 9081711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity.
    Gu J; Andreeff M; Roth JA; Fang B
    Gene Ther; 2002 Jan; 9(1):30-7. PubMed ID: 11850720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954.
    de Poorter JJ; Tolboom TC; Rabelink MJ; Pieterman E; Hoeben RC; Nelissen RG; Huizinga TW
    J Gene Med; 2005 Nov; 7(11):1421-8. PubMed ID: 15977303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
    Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
    Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenovirus-mediated HSV-TK gene therapy using the human telomerase promoter induced apoptosis of small cell lung cancer cell line.
    Song JS; Kim HP
    Oncol Rep; 2004 Aug; 12(2):443-7. PubMed ID: 15254714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo.
    Gu J; Zhang L; Huang X; Lin T; Yin M; Xu K; Ji L; Roth JA; Fang B
    Oncogene; 2002 Jul; 21(31):4757-64. PubMed ID: 12101414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
    Palmer DH; Mautner V; Mirza D; Oliff S; Gerritsen W; van der Sijp JR; Hubscher S; Reynolds G; Bonney S; Rajaratnam R; Hull D; Horne M; Ellis J; Mountain A; Hill S; Harris PA; Searle PF; Young LS; James ND; Kerr DJ
    J Clin Oncol; 2004 May; 22(9):1546-52. PubMed ID: 15051757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.
    Lipinski KS; Djeha AH; Krausz E; Lane DP; Searle PF; Mountain A; Wrighton CJ
    Gene Ther; 2001 Feb; 8(4):274-81. PubMed ID: 11313801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
    Bilsland AE; Merron A; Vassaux G; Keith WN
    Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
    Lanson NA; Friedlander PL; Schwarzenberger P; Kolls JK; Wang G
    Cancer Res; 2003 Nov; 63(22):7936-41. PubMed ID: 14633724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
    Westphal EM; Ge J; Catchpole JR; Ford M; Kenney SC
    Cancer Gene Ther; 2000 Jan; 7(1):97-106. PubMed ID: 10678362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
    Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ
    Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
    Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
    Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of cell cycle- and differentiation stage-dependent human telomerase reverse transcriptase expression in single living cancer cells.
    Edqvist A; Rebetz J; Järås M; Rydelius A; Skagerberg G; Salford LG; Widegren B; Fan X
    Mol Ther; 2006 Jul; 14(1):139-48. PubMed ID: 16584924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
    Benouchan M; Do Nascimento F; Perret GY; Colombo BM
    Int J Oncol; 2006 Feb; 28(2):457-62. PubMed ID: 16391801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.